ZED1227, a selective and orally active TG2 inhibitor, has entered clinical trials for celiac disease and demonstrated favorable pharmacokinetics, target engagement, and tolerability in humans (Schuppan et al., 2021). This evidence concerns the gene TGM2 and celiac disease.